ID: ALA4227754

Max Phase: Preclinical

Molecular Formula: C27H29FN6O4

Molecular Weight: 520.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)c(CCC(=O)NCC3(CO)CC3)c2)NC(=O)N1

Standard InChI:  InChI=1S/C27H29FN6O4/c1-15-23(25(37)32-19-4-6-21-18(11-19)12-30-34-21)24(33-26(38)31-15)17-2-5-20(28)16(10-17)3-7-22(36)29-13-27(14-35)8-9-27/h2,4-6,10-12,24,35H,3,7-9,13-14H2,1H3,(H,29,36)(H,30,34)(H,32,37)(H2,31,33,38)

Standard InChI Key:  MRFFVYCGQCPHFX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 520.57

Molecular Weight (Monoisotopic): 520.2234

AlogP: 2.79

#Rotatable Bonds: 9

Polar Surface Area: 148.24

Molecular Species: NEUTRAL

HBA: 5

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.03

CX Basic pKa: 1.71

CX LogP: 0.78

CX LogD: 0.78

Aromatic Rings: 3

Heavy Atoms: 38

QED Weighted: 0.26

Np Likeness Score: -1.59

References

1. Waldschmidt HV, Bouley R, Kirchhoff PD, Lee P, Tesmer JJG, Larsen SD..  (2018)  Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors.,  28  (9): [PMID:29627263] [10.1016/j.bmcl.2018.03.082]

Source

Source(1):

• Scientific Literature